Scott W. Powers, PhD; Susmita M. Kashikar-Zuck, PhD; Janelle R. Allen, MS; et al.
JAMA. 2013;310(24):2622-2630. doi:10.1001/jama.2013.282533
Powers and coauthors report the results of a randomized controlled trial on cognitive behavioral therapy (CBT) plus amitriptyline for chronic migraine in children and adolescents. In an accompanying Editorial, Connelly discusses the treatment of chronic migraine.
Audio Author Interview:
Cognitive Behavioral Therapy Plus Amitriptyline for Chronic Migraine in Children and Adolescents
Joseph Poole, MD, PhD; Kreton Mavromatis, MD; José N. Binongo, PhD; et al.
JAMA. 2013;310(24):2631-2639. doi:10.1001/jama.2013.282540
Poole and coauthors performed a phase 2, double-blind, placebo-controlled study among 159 patients with peripheral artery disease and intermittent claudication to investigate whether mobilization of bone marrow progenitor cells using granulocyte-macrophage colony-stimulating factor improved exercise capacity.
Henry P. Parkman, MD; Mark L. Van Natta, MHS; Thomas L. Abell, MD; et al.
JAMA. 2013;310(24):2640-2649. doi:10.1001/jama.2013.282833
To determine whether treatment with nortriptyline results in symptomatic improvement of idiopathic gastroparesis, Parkman and coauthors randomized 130 adult patients with idiopathic gastroparesis to receive nortriptyline or placebo.
Edna B. Foa, PhD; Carmen P. McLean, PhD; Sandra Capaldi, PsyD; et al.
JAMA. 2013;310(24):2650-2657. doi:10.1001/jama.2013.282829
To examine the effects of counselor-delivered prolonged exposure therapy for adolescents with posttraumatic stress disorder (PTSD), Foa and coauthors conducted a single-blind, randomized clinical trial among 61 girls with PTSD related to sexual abuse. In an Editorial, Perrin discusses the future of treatments like prolonged exposure therapy.
John L. Berk, MD; Ole B. Suhr, MD, PhD; Laura Obici, MD; et al.
JAMA. 2013;310(24):2658-2667. doi:10.1001/jama.2013.283815
Berk and coauthors conducted an international randomized clinical trial among 130 patients to investigate the effect of diflunisal, a nonsteroidal anti-inflammatory drug, on progression of neurological impairment in familial amyloid polyneuropathy.